Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 in metastatic GIST resistant or intolerant to imatinib
2005-005717-38Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cediranib in gastrointestinal stromal tumor (GIST) and soft tissue sarcoma (STS) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Primary analysis timing and dose-expansion decision. Started Oct 2010; status: completed.
02
Drugs
cediranib
03
Conditions
gastrointestinal stromal tumor (GIST)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2005-005717-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005717-38.